respect cycl
global macro environ show sign slow
america laboratori busi continu lead growth
biopharma demand strong sign slight budget flush
manag increment confid end market
novemb
retail europ dd due comp ex-retail eu would
outlook food retail
thesi updat surfac noth complain
grow revenu nearli ep
averag stock tough comp prior year blame
said guid bit tough us swallow
price-to-earnings post recent correct alway say
fantast world-class compani mind late cycl argu
valuat account acceler hsd core given
comp setup year look quit challeng unless macro
acceler know littl room error valuat
see risk reward particularli favor current despit
market volatil furthermor share return closer histor
market premium share could dip low thu
stay sidelin reiter line rate await better
entri point one day recommend mettler today
unfortun day
condit america eu china
 real chang econom condit sinc last time
 main hw year tough comp china pi
rais ep vs prior due
mm mm share repo
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
 china ok rest year tough
new tax rule allow easier repatri use share repo
biopharma good w/ bit budget flush
industri msd broad strength across region pi modestli
 pi end yr hsd
retail neg impact weak among packag food compani
america strong lab industri retail slightli
europ tough industri retail
apac strong china fy
tax remain around level
benefit lower us rate off-set limit amount deduct
new repatri rule allow bring cash easier repo program
charg mm mm repatri earn paid yr remain non-cash charg
continu favor bolt-on
new tax rule allow easier repatri use share repo
million except per share data fy end decemb organ organ organ organ gp less total op less ep share inc net inc price-to-earnings prem disc februari
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
laboratori corp america hold
articl articl
time dissemin februari et
analyst ross muken vijay kumar luke sergott primarili respons prepar research report attest follow
view opinion render research report reflect person view subject compani issuer
part research analyst compens directli relat specif recommend view research
